US2021085644A1PendingUtilityA1
Treatment for primary biliary cholangitis
Est. expiryDec 9, 2036(~10.4 yrs left)· nominal 20-yr term from priority
A61P 1/16A61K 31/575A61K 9/0053A61K 31/40
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use in treating primary biliary cholangitis; wherein Formula (I) is represented by:
2 . The composition for use according to claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound of Formula (I).
3 . The composition for use according to claim 1 , wherein the compound is a metal cation salt of the compound of Formula (I).
4 . The composition for use according to claim 1 , wherein the compound is saroglitazar magnesium salt.
5 .- 14 . (canceled)
15 . A method of treating primary biliary cholangitis, comprising administering to a subject in need thereof an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, to treat the primary biliary cholangitis; wherein Formula (I) is represented by:
16 . The method of claim 15 , wherein the compound is a pharmaceutically acceptable salt of the compound of Formula (I).
17 . The method of claim 15 , wherein the compound is a metal cation salt of the compound of Formula (I).
18 . The method of claim 15 , wherein the compound is saroglitazar magnesium salt.
19 - 136 . (canceled)Join the waitlist — get patent alerts
Track US2021085644A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.